Shuttle Pharmaceuticals Holdings (SHPH) Cash from Financing Activities (2021 - 2026)
Shuttle Pharmaceuticals Holdings (SHPH) posted quarterly Cash from Financing Activities of $3.2 million for Q1 2026, down 37.31% year-over-year from $5.1 million in Q1 2025, and up 41.43% quarter-over-quarter from $2.3 million in Q4 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $3.2 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 37.31% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $9.0 million (up 1.43% YoY), while the FY2025 annual figure was $11.0 million, up 191.66% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $3.2 million, up from $2.3 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $10.1 million in Q3 2022, with the low at -$461667.0 in Q2 2024.
- The 5-year median for Cash from Financing Activities is $525715.0 (2022), against an average of $2.1 million.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities sank 396.48% in 2023, then soared 12898.47% in 2025.
- Shuttle Pharmaceuticals Holdings' Cash from Financing Activities stood at -$67363.0 in 2022, then tumbled by 396.48% to -$334444.0 in 2023, then jumped by 1431.66% to $4.5 million in 2024, then slumped by 49.05% to $2.3 million in 2025, then soared by 41.43% to $3.2 million in 2026.
- Business Quant data shows SHPH's Cash from Financing Activities at $3.2 million in Q1 2026, $2.3 million in Q4 2025, and -$96375.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Shuttle Pharmaceuticals Holdings | 1.93 Mn | 1.93 Mn | - | 3.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.21 Mn |
| Mar 31, 2026 | 3.21 Mn |
| Dec 31, 2025 | 2.27 Mn |
| Dec 31, 2025 | 2.27 Mn |
| Sep 30, 2025 | -96,375.00 |
| Sep 30, 2025 | -96,375.00 |
| Jun 30, 2025 | 3.66 Mn |
| Jun 30, 2025 | 3.66 Mn |
| Mar 31, 2025 | 5.12 Mn |
| Mar 31, 2025 | 5.12 Mn |
| Dec 31, 2024 | 4.45 Mn |
| Dec 31, 2024 | 4.45 Mn |
| Sep 30, 2024 | -196,790.00 |
| Sep 30, 2024 | -196,790.00 |
| Jun 30, 2024 | -461,667.00 |
| Jun 30, 2024 | -461,667.00 |
| Mar 31, 2024 | -40,000.00 |
| Mar 31, 2024 | -40,000.00 |
| Dec 31, 2023 | -334,444.00 |
| Dec 31, 2023 | -334,444.00 |